Achillion Raises $41.8M Through Stock Offering

E-mail Print PDF
NEW HAVEN — Achillion Pharmaceuticals Inc. has entered into a definitive agreement with funds managed by "http://www.lanepl.org/lib//#generic_">generic Financial LP for the sale of 6,367,853 shares of its common stock.

The investors have agreed to purchase the shares of common stock at a price of $6.57 per share, resulting in " /files//_onlineonline proceeds to Achillion of approximately $41.8 million. The sale was expected to close on "blog/buyvalium//#"> about September 4, subject to closing conditions.

The securities described above are being offered directly to the purchasers by Achillion pursuant to a registration statement previously filed with and subsequently declared effective by the Securities & Exchange Commission.

Achillion is a pharmaceutical developer focused on new treatments for patients with infectious disease, including HCV and resistant bacterial infections.

 
Should Connecticut Give Special Incentives to Individual Companies?
 

Google Search



If you aren't receiving your subscription, or you would like to cancel or change the address please contact us at:

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

or fax 203-781-3482

Please provide you correct address and phone number.


To CANCEL your subscriptions please send an email with your current address for a single family home or name and address for a multi-family home, or business Indicate you want to cancel the subscription.

send the email to This e-mail address is being protected from spambots. You need JavaScript enabled to view it

To purchase a subscription, follow the link under About Us on the home page to a secure ecommerce site, managed by google.com